drugset / Trial / NCT01621945
Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 in Patients Having to be Vaccinated MenBVac® (Extension EFFIVAC)
Phase 3
Completed
120 enrolled
University Hospital, Rouen
Direction Générale de la Santé, France · collabInstitut Pasteur · collab
NaSingle-groupOpen-labelHealth-services research
Summary
The main objective of the study is to estimate the proportion of children, born between the 06/04/2004 and the 17/004/2008, living around Neufchatel en Bray, vaccinated by MenBVac, with a serum bactericidal activity against B:14,P1-7,16 clone related to a protection (\>= 4), before the fourth dose of MenBvac and after: 6 weeks and one year after the fourth dose.
Timeline
- Start
- 2012-04
- Primary completion
- 2013-04
- Completion
- 2013-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MenBVac | Vaccine | — | — |